Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium hyaluronate + xanthan gum is a combined eye gel formulation that contains sodium hyaluronate 0.15% and xanthan gum 1%. This combination leverages the properties of both polysaccharides to create an effective ophthalmic preparation. The formulation accelerates the recovery of corneal epithelial defects and reduces patient complaints when used after procedures such as pterygium surgery. In some commercial products like Xanternet, this combination is supplemented with netilmycine 0.3% to provide additional antimicrobial properties. The combination works through multiple mechanisms: - Sodium hyaluronate provides excellent moisturizing and lubricating properties - Xanthan gum acts as a thickening agent, stabilizer, and suspending agent - Together, they create a gel with pseudoplastic properties that adheres well to the ocular surface - The formulation helps maintain hydration of the corneal epithelium, promoting faster healing
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium hyaluronate + xanthan gum.